Abstract:Disease-specific autoantibodies are considered the most important biomarkers for systemic sclerosis (SSc), due to their ability to stratify patients with different severity and prognosis. Anti-nuclear antibodies (ANA), occurring in subjects with isolated Raynuad's phenomenon, are considered the strongest independent predictors of definite SSc and digital microvascular damage, as observed by nailfold videocapillaroscopy. ANA are present in more than 90% of SSc, but ANA negativity does not exclude SSc diagnosis: a little rate of SSc ANA negative exists and shows a distinct subtype of disease, with less vasculopathy, but more frequent lower gastrointestinal involvement and severe disease course. Anti-centromere, anti-Th/To, and anti-Topoisomerase I antibodies could be considered as classical biomarkers, covering about 60% of SSc and defining patients with well-described cardio-pulmonary complications. In particular, anti-Topoisomerase I represent a risk factor for development of diffuse cutaneous involvement and digital ulcers in the first 3 years of disease, as well as severe interstitial lung disease (ILD). Anti-RNA polymerase III is a biomarker with new clinical implications: very rapid skin thickness progression, gastric antral vascular ectasia, the occurrence of synchronous cancers, and possible association with silicone breast implants rupture. Moreover, novel SSc specific autoantibodies have been globally described in about 10% of "seronegative" SSc patients: anti-elF2B, anti-RuvBL1/2 complex, anti-U11/U12 RNP, and anti-BICD2 depict specific SSc subtypes with severe organ complications. Many autoantibodies could be considered markers of overlap syndromes, including SSc. Anti-Ku are found in 2-7% of SSc, strictly defining the PM/SSc overlap. They are associated with synovitis, joint contractures, myositis, and negatively associated with vascular manifestation of disease. Anti-U3RNP are associated with a well-defined clinical phenotype: Afro-Caribbean male patients, younger at diagnosis, and higher risk of pulmonary hypertension and gastrointestinal involvement. Anti-PM/Scl define SSc patients with high frequency of ILD, calcinosis, dermatomyositis skin changes, and severe myositis. The accurate detection of autoantibodies SSc specific and associated with overlap syndromes is crucial for patients' stratification. ANA should be correctly identified using indirect immunofluorescent assay and a standardized way of patterns' interpretation. The gold-standard technique for autoantibodies' identification in SSc is still considered immunoprecipitation, for its high sensitivity and specificity, but other assays have been widely used in routine practice. The identification of SSc autoantibodies with high diagnostic specificity and high predictive value is mandatory for early diagnosis, a specific follow-up and the possible definition of the best therapy for every SSc subsets. In addition, the validation of novel autoantibodies is mandatory in wider cohorts in order to restrict the gap of so-called seronegative SSc patients.

New centromere autoantigens identified in systemic sclerosis using centromere protein microarrays

Classical Disease-Specific Autoantibodies In Systemic Sclerosis: Clinical Features, Gene Susceptibility, And Disease Stratification

Evaluation of anti-CENP reactivity in samples with centromere HEp-2 pattern and correlation with Systemic Sclerosis clinical features.

Systemic sclerosis and primary biliary cholangitis share an antibody population with identical specificity

Centromere defects, chromosome instability, and cGAS-STING activation in systemic sclerosis

Identification of new telomere- and telomerase-associated autoantigens in systemic sclerosis

[Significance of Anti-Tubulin-α-1c Autoantibody in Systemic Sclerosis].

[Clinical and immunological features of primary Sjögren's syndrome patients with positive anti-centromere protein B antibody]

Pathogenic role of anti‐nuclear autoantibodies in systemic sclerosis: Insights from other rheumatic diseases

Presence Of Anti-Eukaryotic Initiation Factor-2b, Anti-Ruvbl1/2 And Anti-Synthetase Antibodies In Patients With Anti-Nuclear Antibody Negative Systemic Sclerosis

Anti-C1q autoantibodies are frequently detected in patients with systemic sclerosis associated with pulmonary fibrosis

Clinical and serological features of systemic sclerosis in a Chinese cohort

Anti-topoisomerase, but not anti-centromere B cell responses in systemic sclerosis display active, Ig-secreting cells associated with lung fibrosis

Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers

Distinct T cell chromatin landscapes in scleroderma subtypes

Autoantibodies to nuclear valosin-containing protein-like protein: systemic sclerosis-specific antibodies revealed by in vitro human proteome

Identification of two autoantigens recognised by circulating autoantibodies as potential biomarkers for diagnosing giant cell arteritis

Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc)

P140 IgG Autoantibodies with Increased Affinity for Epithelial Cells in Severe Systemic Sclerosis

Anti-citrullinated alpha-enolase peptide 1 antibody in the diagnosis of rheumatoid arthritis

Identification of circulating autoantibodies to non-modified proteins associated with ACPA status in early rheumatoid arthritis